诺和诺德三季报营收最大“功臣”司美格鲁肽亮相进博会

广州日报11-07

诺和诺德三季报再次让业界看到司美格鲁肽这款明星产品的市场潜力。11月6日，诺和诺德发布的三季报显示：营收同比增长23%，最大增长动力来自司美格鲁肽，占到诺和诺德营收的69%。在全球发布三季报的同时，诺和诺德正在携司美格鲁肽这款大单品亮相进博会。此次中国首展包括全球首个且目前唯一GLP-1受体激动剂司美格鲁肽片（商品名：诺和忻）和全球首个用于长期体重管理的GLP-1周制剂——诺和盈，即用于长期体重...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481948766?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-07 13:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481948766","market":"us","top_or_hot":-1,"title":"诺和诺德三季报营收最大“功臣”司美格鲁肽亮相进博会","media":"广州日报","content":"<div>\n<p>诺和诺德三季报再次让业界看到司美格鲁肽这款明星产品的市场潜力。11月6日，诺和诺德发布的三季报显示：营收同比增长23%，最大增长动力来自司美格鲁肽，占到诺和诺德营收的69%。在全球发布三季报的同时，诺和诺德正在携司美格鲁肽这款大单品亮相进博会。此次中国首展包括全球首个且目前唯一GLP-1受体激动剂司美格鲁肽片（商品名：诺和忻）和全球首个用于长期体重管理的GLP-1周制剂——诺和盈，即用于长期体重...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202411073232501139.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德三季报营收最大“功臣”司美格鲁肽亮相进博会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德三季报营收最大“功臣”司美格鲁肽亮相进博会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 13:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202411073232501139.html><strong>广州日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德三季报再次让业界看到司美格鲁肽这款明星产品的市场潜力。11月6日，诺和诺德发布的三季报显示：营收同比增长23%，最大增长动力来自司美格鲁肽，占到诺和诺德营收的69%。在全球发布三季报的同时，诺和诺德正在携司美格鲁肽这款大单品亮相进博会。此次中国首展包括全球首个且目前唯一GLP-1受体激动剂司美格鲁肽片（商品名：诺和忻）和全球首个用于长期体重管理的GLP-1周制剂——诺和盈，即用于长期体重...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202411073232501139.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"http://finance.eastmoney.com/a/202411073232501139.html","article_id":"2481948766","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481948766","pubTimestamp":1730957134,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"诺和诺德三季报再次让业界看到司美格鲁肽这款明星产品的市场潜力。11月6日，诺和诺德发布的三季报显示：营收同比增长23%，最大增长动力来自司美格鲁肽，占到诺和诺德营收的69%。在全球发布三季报的同时，诺和诺德正在携司美格鲁肽这款大单品亮相进博会。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"Novo Nordisk's biggest \"contributor\" to revenue in the third quarter report, semaglutide, appeared in China International Import Expo","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"诺和诺德三季报再次让业界看到司美格鲁肽这款明星产品的市场潜力。11月6日，诺和诺德发布的三季报显示：营收同比增长23%，最大增长动力来自司美格鲁肽，占到诺和诺德营收的69%。在全球发布三季报的同时，诺和诺德正在携司美格鲁肽这款大单品亮相进博会。此次中国首展包括全球首个且目前唯一GLP-1受体激动剂司美格鲁肽片（商品名：诺和忻）和全球首个用于长期体重管理的GLP-1周制剂——诺和盈，即用于长期体重管理的司美格鲁肽注射液。　　诺和诺德全球高级副总裁兼大中国区总裁周霞萍表示：诺和诺德一直在不断引领GLP-1类药物的研发突破。此次进博会上，诺和诺德启动“健康中国行动——代谢焕新元年”活动。通过进博会平台，诺和诺德见证了众多创新药加速落地中国甚至同步获批、完成从“展品”到“商品”的转变，也在公众科普教育方面实现了开拓创新。　　此外，就财报而言，单季度来看，诺和诺德第三季度收入713.11亿丹麦克朗，同比增长22%，净利润273.01亿丹麦克朗，同比增长21%，高于市场预期。或受上述消息影响，11月6日美股盘前，诺和诺德最高涨超6%。前三季度整体来看，诺和诺德收入2047.2亿丹麦克朗，同比增长23%；净利润727.58亿丹麦克朗，同比增长18%。（文章来源：广州日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481948766"}